Daré Bioscience to Begin Dispensing DARE to PLAY Sildenafil Cream in 28 States

Daré Bioscience (DARE) has announced that dispensing for its product, DARE to PLAY Sildenafil Cream, is scheduled to commence in November across 28 states where its outsourcing facility holds active licenses. This move marks a significant step in the company's commercialization efforts alongside the existing market presence of Flora Sync LF5. Financially, the company reported third-quarter revenue of $48,000 and a net loss of $3.2 million, ending the period with $11.5 million in cash and cash equivalents. Looking ahead, management is focusing on channel diversification for Flora Sync LF5—including potential Amazon availability in 2027—while awaiting clinical readouts for Ovaprene and DARE-HPV scheduled for 2027.

Seeking Alpha ·

Daré Bioscience to Begin Dispensing DARE to PLAY Sildenafil Cream in 28 States

Tickers: $DARE

Topics: cash position commercialization product launch revenue report

Read the full article at Seeking Alpha

More World news